An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne

November 28, 2016 updated by: Mahidol University

An Evaluator-blind, Randomized, Vehicle-controlled Efficiency of Adjunctive Usage of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel for Improvement of Local Tolerance in Thai Acne Subjects

Acne is an inflammation of sebaceous glands and follicles. Applying topical treatments such as adapalene gel may cause irritant adverse effects. Hence, using a moisturizer is another way to protect or relieve this undesirable event. Moisturizers that have anti-inflammatory property could reduce irritant effects, emergent from using topical treatment and also reduce severity of acne.

Research teams chose an adapalene gel to act as topical treatment for curing acne. It has anti-inflammatory and comedolytic effects and has fewer side effects than other groups of topical retinoic acids. However, peeling skin, redness skin, tingling sensation or itching sensation may occur if they are continually used for a long period. Thus, for the purpose of studying the efficacy of moisturizer containing licochalcone A, L-carnitine and 1,2-decanediol in reducing irritant effect of using adapalene gel (Licochalcone A has anti-inflammatory effect, L-carnitine decrease sebum production and 1,2-decanediol has anti-bacterial effect).

Study Overview

Detailed Description

The investigators team research with patients by separate patients into 3 groups and compare among each other. In the first group use only adapalene gel, the second group use adapalene gel with moisturizer containing three substances mentioned above, and the last group use adapalene gel with placebo moisturizer. To compare outcomes among 3 groups, the investigators will measure degree of redness, scale, oily face, moist, number of acne, quality of life, and satisfaction after using moisturizer.

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bangkok, Thailand, 10700
        • Siriraj Hospital Mahidol Univeristy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age 18 years old or above
  2. Participants have to control the birth for example, condom method, intrauterine device method before participate in the research at least 1 month until 6 months after research finish.
  3. being diagnosed acne vulgaris by dermatologist in mild to moderate degree based on Investigators' Global Assessment scale of FDA

Exclusion Criteria:

  1. Use oral or injected antibiotics or other oral medicine treating acne for example, isotretinoin, oral contraceptives, or spironolactone group during 4 weeks before participate this research
  2. Have other active skin diseases at face during 2 weeks before participate the research
  3. Allergic to adapalene gel and moisturizer
  4. Have severe or uncontrolled underlying diseases
  5. Getting pregnant or during breast feeding
  6. Other types of acne(not acne vulgaris)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Adapalene gel

Evening

  • Wash face by prepared facial foam and dry your face
  • Apply adapalene gel all over the face
Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
Other Names:
  • Adapalene gel (Differin)
Placebo Comparator: Adapalene gel with placebo moisturizer

Morning

  • Wash face by prepared facial foam and dry their face
  • Apply placebo cream all over the face

Evening

  • Wash face by prepared facial foam and dry your face
  • Apply adapalene gel all over the face
  • Apply placebo cream all over the face
Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
Other Names:
  • •Adapalene gel (Differin)
Active Comparator: Adapalene gel with Eucerin

Morning

  • Wash face by prepared facial foam and dry their face
  • Apply Eucerin cream all over the face

Evening

  • Wash face by prepared facial foam and dry your face
  • Apply adapalene gel all over the face
  • Apply Eucerin cream all over the face
Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
Other Names:
  • licochalcone A + L-carnitine + decanediol (Eucerin)
  • Adapalene gel (Differin)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction of Undesirable Effects
Time Frame: 2nd week, 4th week, and 8th week
  • Undesirable effects were evaluated from skin's condition/signs(erythema, dryness and scaling) are evaluated by dermatologist. (none; mild; moderate; severe) and subject interview/symptoms(stinging/burning and pruritis) are evaluated by participants.(none; mild; moderate; severe). There were assessed at 2nd week, 4th week, and 8th week.
  • The worst score of each parameter which was defined as the worst local tolerance score is demonstrated and compared among 3 groups as shown.
2nd week, 4th week, and 8th week
Skin Tolerability: Skin Sebum Content and Skin Hydration
Time Frame: Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.
Skin tolerability was assessed by measuring the skin surface sebum content, skin hydration with the Sebumeter SM815 and Corneometer CM825, respectively
Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.
Skin Tolerability: Transepidermal Water Loss (TEWL)
Time Frame: Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.
Skin tolerability was assessed by measuring TEWL with the Tewameter TM300
Skin tolerability was assessed at baseline and week 8. The changes of skin tolerability between baseline and 8th week of the 3 groups were compared.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction of Severity of Acne
Time Frame: baseline, 2nd week, 4th week and 8th week
  • Evaluation from mean counts of inflammatory, noninflammatory, and total acne lesions at baseline, and at 2, 4, and 8 weeks
  • Total acne lesions = inflammatory + noninflammatory acne lesions
  • Reduction of lesions counts are considered to be a better outcome
baseline, 2nd week, 4th week and 8th week
Reduction of Severity of Acne: Acne Severity Index (ASI)
Time Frame: baseline, 2nd week, 4th week and 8th week
  • The ASI score was calculated from the number of papules + (2 x pustules) + (comedones/4)
  • Decrease of ASI score are considered to be a better outcome
baseline, 2nd week, 4th week and 8th week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2014

Primary Completion (Actual)

February 1, 2015

Study Completion (Actual)

July 1, 2015

Study Registration Dates

First Submitted

June 18, 2014

First Submitted That Met QC Criteria

June 23, 2014

First Posted (Estimate)

June 24, 2014

Study Record Updates

Last Update Posted (Estimate)

January 23, 2017

Last Update Submitted That Met QC Criteria

November 28, 2016

Last Verified

November 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acne

Clinical Trials on Adapalene gel

Subscribe